R&D

30 Years of HIV: but who made the discovery?

30 Years of HIV: but who made the discovery?

Written by on April 23, 2014 in R&D with 0 Comments

It has been 30 years to the day since Dr Robert Gallo, MD and colleagues from the Institute of Human Virology at the University of Maryland announced at a press conference that they had discovered the cause of AIDS: HIV Gallo’s announcement 30 years ago came at a trying time across the world as the […]

Continue Reading

Highlights of the 14th World Vaccine Congress – A Cell Culture Perspective

Highlights of the 14th World Vaccine Congress – A Cell Culture Perspective

Written by on April 16, 2014 in R&D with 0 Comments

Highlights of the 14th World Vaccine Congress – A Cell Culture Perspective The World Vaccine Congress is the World’s leading conference that covers all elements of vaccine research, development, manufacture and distribution. This report by Cell Culture Dish focuses in on the discussions that took place around cell culture, looking at key presentations such as: […]

Continue Reading

Therapeutic

GSK Gives Up On Flagship Cancer Vaccine MAGE-A3

GSK Gives Up On Flagship Cancer Vaccine MAGE-A3

Written by on April 2, 2014 in Press Releases, Therapeutic Vaccines with 0 Comments

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer April 2, 2014 GlaxoSmithKline plc today announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a […]

Continue Reading

GSK Cancer Vaccine Fails to Meet Phase III Primary Endpoints Again

GSK Cancer Vaccine Fails to Meet Phase III Primary Endpoints Again

Written by on March 20, 2014 in Press Releases, Therapeutic Vaccines with 0 Comments

Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population March 20, 2014 GlaxoSmithKline plc (GSK) today announced that analysis […]

Continue Reading

Prophylactic

Infographic: Shingles – how real are the risks?

Infographic: Shingles – how real are the risks?

Written by on April 1, 2014 in Prophylactic Vaccines with 0 Comments

Sanofi Pasteur recently published this snazzy infographic on the risk posed by the Shingles virus, so we thought we’d share it with you:

Continue Reading

80% of the World’s Population live in Polio Free Regions: South-East Asia given the all clear

80% of the World’s Population live in Polio Free Regions: South-East Asia given the all clear

Written by on March 27, 2014 in Prophylactic Vaccines with 0 Comments

The World Health Organization have certified the WHO South-East Asia region as polio-free The World Health Organization (WHO) has announced today that the South-East Asia region (SEAR) has been declared officially polio-free. “This is a momentous victory for the millions of health workers who have worked with governments, non-governmental organizations, civil society and international partners […]

Continue Reading

Flu

Requirements for flu virus stock for human administration in clinical trials

Requirements for flu virus stock for human administration in clinical trials

Written by on April 17, 2014 in Flu with 0 Comments

Jeff Ryel, RN – SGS Life Science Services joined us last year at the World Vaccine Congress Europe to present on ‘Requirements for flu virus stock for human administration in clinical trials’ Download this presentation now to find out more about: GMP production regulatory requirements Lab quality and safety testing requirements Clinical validation requirements Clinical […]

Continue Reading

Tamiflu: a waste of £500 million?

Tamiflu: a waste of £500 million?

Written by on April 16, 2014 in Flu with 0 Comments

Annual vaccination is the best strategy to prevent influenza. However, as the vaccine industry continues to work towards developing a Universal Flu Vaccine, it is important to consider the available treatment options and subsequently to make sure that the public is kept up-to-date with the options available to them. Last week, the UK media was alight […]

Continue Reading

Regulation & Policy

20% of Americans Believe in a Vaccine Conspiracy

20% of Americans Believe in a Vaccine Conspiracy

Written by on March 27, 2014 in Regulation and Policy with 0 Comments

A report published in JAMA Internal Medicine suggests that 20% of the American public believe that doctors and the government know that vaccines cause harm, and yet they continue to inoculate children.  The survey found that, of the 1351 participants, 69% had heard of this conspiracy theory, making it the most widely known medical conspiracy theory mentioned […]

Continue Reading

Canada Launches Official Vaccination iPhone App

Canada Launches Official Vaccination iPhone App

Written by on March 21, 2014 in Featured on App, Regulation and Policy, Supply Chain with 0 Comments

Yesterday the Honourable Rona Ambrose, Minister of Health at the Canadian Public Health Association, launched a new vaccination app for Apple iPhone and google android users: ImmunizeCA. The app, produced in partnership with Immunize Canada and the Ottawa Hospital Research Institute, is designed to give Canadians a tool through which they can track the vaccinations […]

Continue Reading

Emerging Markets

Viral hepatitis gives Asia-Pacific a wake-up call

Viral hepatitis gives Asia-Pacific a wake-up call

Following a forum held last month by the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), health experts have urged the Asia-Pacific countries to set actions against viral hepatitis as a public health priority. Recognizing the financial barriers in formulating national strategies based on the WHO framework, Jennifer Johnston, the organization’s Executive Director, stressed […]

Continue Reading

The Bystander Effect: do rotavirus infections lead to type I diabetes?

The Bystander Effect: do rotavirus infections lead to type I diabetes?

Written by on April 8, 2014 in Emerging Markets, R&D with 0 Comments

Research, lead by Associate Professor Barbara Coulson of Peter Doherty Institute for Infection and Immunity, University of Melbourne, has found a co-relation between rotavirus and Type I diabetes. Both diseases are usually diagnosed in children. Rotavirus is a deadly form of sever diarrhoea, whilst Type I diabetes, previously known as juvenile diabetes, is a chronic […]

Continue Reading

Supply Chain

Fingerprint Scanning Leads to Improved Vaccination Rates in West Africa

Fingerprint Scanning Leads to Improved Vaccination Rates in West Africa

Written by on March 17, 2014 in Supply Chain with 0 Comments

lumidigm multispectral imaging fingerprint sensors have now been installed at 31 clinics across southern Benin, West Africa. These scanners were developed in coordination with VaxTrac, and through a combination of the latest vaccine record keeping software and lumidigm’s fingerprint sensors, the hope is that vaccine waste can be decreased from the 50% found in many […]

Continue Reading

No Ice? No Problem: Vaccines successfully endure African heat

No Ice? No Problem: Vaccines successfully endure African heat

Written by on February 19, 2014 in Press Releases, Supply Chain with 0 Comments

A trial using 15,000 vials of MenAfriVac  has successfully shown that the vaccines can survive the ‘last leg’ of the vaccine’s journey in nothing more than a picnic cooler. The trial, published today in Vaccine, examined the effects of this approach, called a  ‘controlled temperature chain‘ (CTC), on a drive across Benin to vaccinate against  meningococcal bacterium Neisseria […]

Continue Reading

Downloads

Round up from the World Vaccine Congress 2014

Round up from the World Vaccine Congress 2014

Written by on April 1, 2014 in Reports with 0 Comments

So the World Vaccine Congress is over for its 14th year! With 80+ speakers, 40+ sponsors and over 60 sessions of scientific, corporate development and future-looking content, it was a busy few days! Opening with Dr Gregory Poland from the Mayo Clinic talking about the future of vaccinology, right from the start the focus was […]

Continue Reading

White Paper: Scaling-up Influenza: Improving manufacturing agility with GE Healthcare

White Paper: Scaling-up Influenza: Improving manufacturing agility with GE Healthcare

Written by on February 14, 2014 in Flu, Reports, Supply Chain with 0 Comments

Overview of a scale-up of a cell-based influenza virus production process using ReadyToProcess equipment posted on behalf of GE Healthcare Life Sciences “The aim of this white paper is to demonstrate how GE Healthcare Life Sciences single-use products can be applied in the field of vaccine manufacturing. The white paper includes a brief discussion around modern […]

Continue Reading

Other Recent Posts

Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT

Results expected for Q3, 2014 April 23, 2014 Anergis, a company discovering and developing proprietary allergy vaccines, today announced that it has completed the enrolment of 196 subjects in the long-term efficacy trial of its birch pollen allergy vaccine AllerT, and expects to release results in the third quarter of 2014. The long-term efficacy trial […]

Continue Reading

Celldex’s Phase 1 Study of CDX-1401 Published in Science Translational Medicine

First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity April 16, 2014 Celldex Therapeutics, Inc. announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). […]

Continue Reading

GSK Acquires Novartis’ Global Vaccines Business for $5.25 Billion as Part Larger Reshuffle

GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders April 22, 2014 GlaxoSmithKline plc today announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses (the “Transaction”). In summary: GSK and Novartis will create a […]

Continue Reading

Top
Geolocation